A Double-Masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's Disease. Ocul Immunol Inflamm, 15, 63-70. presented at the 03-04/2007. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17558830. (2007).
Uveitis therapy: a phase II study using subcutaneously administered daclizumab. presented at the 2004.. (2004).
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun, 21, 283-293. presented at the 2003.. (2003).